tbuckley/cabot-search huggingface dataset:
Abstract 4954: The expression of X-linked inhibitor of apoptosis in human oral squamous cell carcinoma and its relationship with clinical factors
Authors: Tetsuya Tamatani, Natsumi Takamaru, Daisuke Uchida, Hirokazu Nagai, Kenji Fujisawa, Youji Miyamoto
Journal: Cancer Research (2012)

Abstract [Background] X-linked inhibitor of apoptosis (XIAP) is a member of the inhibitor of apoptosis protein family, which is associated with cell survival by blocking caspase-mediated apoptosis. XIAP is expressed in various malignant tumors. The overexpression of XIAP has been reported to be a poorer prognostic factor in various malignancies. However, the prognostic value of XIAP expression in patients with oral cancer is not still cleared. [Purpose] The aims of present study were to evaluate the expression of XIAP protein in oral squamous cell carcinoma (OSCC) and to elucidate the relationships among the XIAP expression, clinical stages, histological differentiation and classification of invasion mode. [Materials and Methods] Four human OSCC cell lines, B88, CAL27, HNt, and HSC3 cells were used in this study. Normal gingival epithelial cells served as control. XIAP expression of cultured cells was detected by western blot. Tissue specimens were obtains from 85 patients with OSCC after surgery or biopsy. XIAP expression was detected by an immunohistochemical method. [Results] The expression of XIAP was detected in all cancer cells, but not in normal cells. Immunohistochemical analysis of 85 cases of OSCC showed that 73 (86%) cases expressed XIAP. There was no relationship between XIAP expression and clinical stages, or classification of invasion mode. There were significant differences between XIAP expression and histological differentiation. Most of non-staining and weakly staining of cancer was well differentiated. In contrast, intense and extensive staining was frequently found in poorly differentiated cancer. [Conclusions] These findings suggested that the expression of XIAP in OSCC could be related to histological differentiation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4954. doi:1538-7445.AM2012-4954
HIGH LEVELS OF FIBRINOGEN, BUT NOT FIBRINOGEN GENETIC VARIANTS PREDICT CORONARY ARTERY DISEASE IN SUBJECTS WITH HYPERTENSION AND DIABETES MELLITUS TYPE 2
Authors: Nikolaos Papageorgiou, Alexandros Briasoulis, George Hatzis, Maria Kozanitou, Marietta Charakida, Antigoni Miliou, Emmanouel Androulakis, Konstantinos Tsioufis, Gerasimos Siasos, Konstantinos Toutouzas, Spyridon Papaioannou, George Latsios, Zoi Pallantza, Christodoulos I Stefanadis, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2015)
Imaging of Nasopharyngeal Carcinoma with Tc-99m MIBI
Authors: MARGARET H. PUI, JIAN QIANG DU, TIAN CHAO YUEH, SHI QUAN ZENG
Journal: Clinical Nuclear Medicine (1998)

Purpose Differentiation of recurrent nasopharyngeal carcinoma (NPC) from radiation fibrosis using conventional diagnostic methods can be difficult. The authors prospectively studied patients with NPC to determine the efficacy of Tc-99m MIBI scintigraphy in detecting the primary, residual, and recurrent tumors. Materials and Methods The authors performed Tc-99m MIBI SPECT studies of the head and neck and whole-body scans on 21 healthy adult volunteers and 43 patients with NPC before (n = 26) or after (n = 17) radiotherapy. The images were qualitatively assessed by comparing the nasopharyngeal uptake to scalp radioactivity. MIBI uptake index was calculated as a ratio of mean counts per pixel in the normal nasopharynx or tumor to mean counts per pixel in the scalp. Results There was significantly higher uptake of Tc-99m MIBI by NPC than normal nasopharynx and radiation fibrosis (P <.05). The authors determined the optimum cutoff MIBI uptake index value of 1.3 with a sensitivity of 97%, a specificity of 100%, a positive predictive value of 100%, a negative predictive value of 96%, and an accuracy of 98% for diagnosing NPC. Conclusion This study suggests that Tc-99m MIBI SPECT is useful for detecting primary NPC and for differentiating residual or recurrent tumor from radiation fibrosis. The authors propose the cutoff MIBI uptake index value of 1.3 for diagnosing NPC.
Abstract 3890: NCI's Clinical Proteomic Tumor Analysis Consortium
Authors: Mehdi Mesri, Emily Boja, Tara Hiltke, Chris Kinsinger, Jerry Lee, Henry Rodriguez
Journal: Cancer Research (2016)

Abstract The NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC) constitutes a network of Proteome Characterization Centers (PCCs), which coordinate and conduct research and data sharing activities to comprehensively interrogate genomically characterized cancer biospecimens. Such integrated proteogenomics approach brings key insights into genomic abnormalities manifested at the protein network and pathway level. Established in late 2011, CPTAC works closely with genomics initiatives such as The Cancer Genome Atlas (TCGA) to systematically identify proteins that derive from alterations in cancer genomes and related biological processes, and provide this data with accompanying assays and protocols to the public. CPTAC investigators conducted the first in-depth comprehensive proteome (global, phosphoproteome and N-glycoproteome) study on understanding the impact of cold ischemia that has resulted in the development of an ischemic signature database and best practice procedures for biospecimen (tissue) sample collection/processing. The PCCs have deeply characterized three cancer types (colorectal, ovarian and breast tumors) previously analyzed by TCGA and additional tissue collections, all of which are accompanied by genomic datasets. Scientific findings examining 95 TCGA colon and rectal tumors using deep proteomic analysis include: a) five proteomic subtypes were identified, with the TCGA MSI/CIMP transcriptomic subtype separated into distinct proteomic subtypes including one subtype (subtype C) that displayed protein network features characteristic of epithelial-mesenchymal transition (EMT); b) copy number alterations (CNAs) on mRNA abundance analysis showed strong cis- and trans-effects; but few extending to the protein level; and c) chromosome 20q amplicon was shown to contain the largest global changes in both mRNA and protein levels, allowing for prioritizing driver genes. In addition to the publicly available proteomic datasets (https://cptac-data-portal.georgetown.edu/cptacPublic), proteomic targeted assays developed by the consortium are available at CPTAC's Assay Portal (http://assays.cancer.gov). This is a public resource of mass spectrometry-based quantitative targeted proteomic assays for measuring proteins of interest from the program. Lastly, monoclonal antibodies targeting cancer specific proteins and peptides are made available at CPTAC's Antibody Portal (http://antibodies.cancer.gov). Citation Format: Mehdi Mesri, Emily Boja, Tara Hiltke, Chris Kinsinger, Jerry Lee, Henry Rodriguez. NCI's Clinical Proteomic Tumor Analysis Consortium. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3890.
994 DEVELOPMENT AND PILOT OF A CHECKLIST FOR MANAGEMENT OF ACUTE LIVER FAILURE IN THE INTENSIVE CARE UNIT
Authors: O.K. Fix, I. Liou, C. Karvellas, D. Ganger, K.A. Forde, R. Subramanian, A. Boylan, J. Hanje, R.T. Stravitz, W.M. Lee
Journal: Journal of Hepatology (2013)
Abstract 3408: The anticancer mechanisms of ciclopirox olamine.
Authors: Tao Shen, Hongyu Zhou, Shile Huang
Journal: Cancer Research (2013)

Abstract Ciclopirox olamine (CPX), a synthetic fungicide clinically used to treat mycoses of the skin and nails, has been demonstrated as a novel anticancer agent. However, the underlying anticancer mechanisms are not well understood. Here we show that CPX suppressed cell proliferation, induced cell death (apoptosis and autophagy), and inhibited cell motility in breast cancer (MDA-MB-231) and rhabdomyosarcoma (Rh30) cells. We observed that CPX induced inhibitory phosphorylation of CDK2 and inhibited cyclin D1 expression, resulting in dephosphorylation of Rb in the tumor cells, which was correlated to cell cycle arrest at G1 phase. Furthermore, we found that CPX caused DNA damage and activated ATR-Chk1 axis, increasing phosphorylation and degradation of Cdc25A, a critical protein involved in the regulation of cell cycle progression and apoptosis. CPX also activated JNK cascade, associated with apoptosis. Moreover, CPX downregulated cellular protein expression of small GTPases (RhoA, Cdc42 and Rac1) and induced inhibitory phosphorylation of FAK, related to cell migration. In addition, we found that CPX inhibited the signaling of mTOR, a central controller of cell proliferation, survival (apoptosis and autophagy) and motility. The results suggest that CPX exerts its anticancer activity by targeting multiple signaling molecules. Citation Format: Tao Shen, Hongyu Zhou, Shile Huang. The anticancer mechanisms of ciclopirox olamine. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3408. doi:10.1158/1538-7445.AM2013-3408
INVESTIGATION OF THE FAMILIAL HYPERCHOLESTEROLEMIA USING DISEASES-SPECIFIC INDUCED PLURIPOTENT STEM CELLS
Authors: Hirofumi Okada, Chiaki Nakanishi, Shohei Yoshida, Masayuki Mori, Kenshi Hayashi, Tsuyoshi Yoshimuta, Hayato Tada, Masa-aki Kawashiri, Masakazu Yamagishi
Journal: Journal of the American College of Cardiology (2015)
Photon-Deficient Bone Metastases in Hepatocellular Carcinoma
Authors: HIROO IKEHIRA, YOSHIAKI FURUICHI, SATOSHI MIZUNO, HIROMI SEGAWA, HIROKAZU NAKAMURA, SHINJIRO KIMURA, SHEIJI YAMAMOTO, HIDEYUKI TAKANO, HISAO ITO, TADASHI AOKI
Journal: Clinical Nuclear Medicine (1998)

Photon deficient areas on bone scans in bone metastases from hepatocellular carcinoma (HCC) have been reported previously. In this report, three different patterns of photopenia in patients with metastatic HCC are seen. Areas of increased uptake as well as photon deficient areas were seen in the metastatic areas on bone imaging.
The Appearance of Malignant Fibrous Histiocytoma on a Three-Phase Bone Scan
Authors: DAVID H. STEMERMAN
Journal: Clinical Nuclear Medicine (1996)

The author describes the case of a 58-year-old woman who had fever and acute onset of right hip pain and was referred for a bone scan to exclude osteomyelitis. Using the three-phase technique with Tc-99m MDP, scintigraphy demonstrated increased flow, soft-tissue uptake, and bone uptake of the radiopharmaceutical at the level of the right iliac wing. This appearance was consistent with an acute infection. However, a subsequent CT scan showed a large soft-tissue mass with bony destruction, questioning the scintigraphic interpretation. A biopsy proved this lesion to be a malignant fibrous histiocytoma.
An unusual cause of dysphagia after endoscopic resection of an early esophageal cancer
Authors: Y. Nakanishi, S. Miyamoto, S. Ishizu, H. Seno, M. Muto, T. Chiba
Journal: Endoscopy (2011)

A 72-year-old man was referred to our hospital for endoscopic treatment of an early esophageal cancer. He had been aware of a submucosal tumor (SMT) in the mid-esophagus for 30 years. Endoscopy revealed that the cancer was located on the surface and had spread distally ([Fig. 1]) [1]. The SMT was visualized as a high-intensity mass on computed tomography (CT), suggesting that it was almost entirely highly calcified. Because the CT scan showed that the SMT was located adjacent to the aorta ([Fig. 2]), only the cancerous part was resected by endoscopic submucosal dissection (ESD), leaving the rest of the SMT untouched ([Fig. 3]) [2]. Although the procedure was completed without complications, 3 months later the patient complained of dysphagia. Endoscopy revealed a giant mass in the esophageal lumen ([Fig. 4]), attached via a narrow pedicle to the ESD scar. We recognized the mass as the original SMT, which had become exposed to the esophageal lumen after the mucosal defect had been repaired. We severed the pedicle with a snare; however, because of its large size, we were unable to remove the tumor through the patient’s mouth. We then failed to disrupt the tumor using several endoscopic devices, including mechanical lithotripsy and electrohydraulic lithotripsy, because of its marked hardness. Fortunately, the tumor was eventually expelled through the anus without causing intestinal obstruction. However, we missed retrieving the tumor from the feces so a histopathologic examination could not be done. Follow-up endoscopy showed only an esophageal ulcer scar without any recurrence or stricture formation ([Fig. 5]).
PWE-172 Factors influencing malnutrition after curative gastrectomy for gastric carcinoma
Authors: K X Cheong, M J Lee, A Shabbir, C S Tan, A Y L Tay, J B Y So
Journal: Gut (2012)

<h3>Introduction</h3> Patients with gastric carcinoma often suffer from malnutrition after curative gastrectomy. It is difficult to identify patients who require further nutritional support as part of their long-term post-operative care because factors influencing weight loss are unknown, and it is also inefficient to directly evaluate the nutritional status of every patient using available screening tools. This study aims to identify factors influencing weight loss after curative gastrectomy, which can be used to efficiently identify at-risk patients to improve outcomes. <h3>Methods</h3> 163 patients (71.8% of those eligible) who underwent curative gastrectomy from 2000 to 2010 at the National University Hospital were identified from a prospectively maintained database. Factors predicting severe malnutrition at 6 months post-gastrectomy (defined as ≥10% loss of pre-operative weight), and factors influencing gain/plateau vs further weight loss over the following 6 months in the patients who were malnourished at 6 months post-gastrectomy were identified with multiple logistic regression. <h3>Results</h3> Severe malnutrition was present in 52.8% (n=86) at 6 months post-gastrectomy. For these patients, those who had anaemia (OR 3.662, p=0.006), gastrointestinal bleeding (OR 2.532; p=0.038) or weight loss (OR 1.052; p=0.010) at presentation, histopathologies of poorly and moderately differentiated tumours (OR 3.632 and 1.757 respectively; p=0.029), adjuvant therapy (OR 8.464; p=0.000), and those requiring step-down care upon discharge (OR 5.739; p=0.021) were at increased risk of weight loss. However, male gender (OR 0.288; p=0.012), vomiting at presentation (OR 0.219; p=0.014), and neo-adjuvant therapy (OR 0.225; p=0.027) were associated with decreased risk. Age, race and operation length were not significant factors at 6 months. Of the patients who were malnourished at 6 months, 54.9% (n=39) developed further weight loss over the subsequent 6 months. Pre-operative total lymphocyte count (OR 2.141; p=0.033) and tumour size (OR 1.235; p=0.054) were associated with increased risk. Age, gender and race were not significant factors at 12 months. <h3>Conclusion</h3> Malnutrition is a significant problem post-gastrectomy. More nutritional care should be provided to patients presenting with acute presentation, poor tumour biology and those requiring adjuvant therapy and step-down care as these are risk factors at 6 months. At 1 year, patients who initially had larger tumour sizes and higher pre-operative total lymphocyte counts are at greater risk of continued weight loss, and should receive further nutritional support as part of their long-term post-operative care. <h3>Competing interests</h3> None declared.
THU0197 Time to recovery from proteinuria in lupus nephritis patients receiving standard of care treatment
Authors: Z. Touma, M.B. Urowitz, D. Ibañez, D.D. Gladman
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The level of proteinuria is an important measure to document improvement in lupus nephritis. The recovery time from abnormal levels of proteinuria has not been well described with standard treatment. <h3>Objectives</h3> To determine: 1) the recovery time from proteinuria in lupus nephritis patients receiving standard treatment and 2) whether the initial level of proteinuria predicts the percentage of patients who improve and the time to improvement. <h3>Methods</h3> We studied all lupus nephritis patients registered at the Lupus Clinic; 1970-2011. Proteinuria was defined as ≥0.5g/24 hours as defined by SLEDAI-2K. Patients with proteinuria and at least one of the urinary sediments (hematuria, pyuria or casts) present at initial visit and persistent on 2 consecutive visits were enrolled. Patients were grouped into: group 1 as 0.5-0.9g/day, group 2 as 1-2g/day and group 3 as ≥2g/day. Recovery from proteinuria was defined as proteinuria &lt;0.5g/24 hours. We determined the time to recovery from proteinuria in all patients and in each of the 3 groups separately with the Kaplan-Meier estimator. <h3>Results</h3> 244 patients (F 95%) were identified. 59% were Caucasian, 16% Black, 14% Asian, and 11% other. Age at diagnosis of lupus was 28.0±12.4 years, age and duration of lupus at start of study was 34.0±12.2 and 6.0±6.5 years, respectively. The mean length of follow-up period was 2.3±2.7 years. SLEDAI-2K was 16.9±6.8 at the start and 7.9±7.2 at the end of the study. 53% of the patients recovered from proteinuria within 2 years while 74% recovered within 5 years (Figure 1). The level of proteinuria at baseline visit predicted the time to improvement and the percentage of patients who improved. Patients with a higher level of proteinuria at baseline needed a longer time to normalize their proteinuria [group 1 (n=21/29): 1.2±0.7 years, group 2 (n=44/74): 1.63±1.79 years and group 3 (n=66/111): 2.83±2.86 years (p=0.004)] (Figure 1). <h3>Conclusions</h3> Almost 50% of the lupus nephritis patients normalize their proteinuria by year 2 and others continue to improve over time; 74% recovered by year 5. The level of proteinuria at baseline visit predicts the percent of patients who respond over time and the time to improvement. <h3>Disclosure of Interest</h3> None Declared
Noncalcified pancreatic stone treated with electrohydraulic lithotripsy using SpyGlass pancreatoscopy
Authors: N. Sasahira, H. Isayama, R. Nagano, H. Kogure, K. Yamamoto, K. Kawakubo, N. Yamamoto, K. Hirano, M. Tada, K. Kubota, K. Koike
Journal: Endoscopy (2011)

Endoscopic removal of pancreatic stones remains challenging, especially when the stones are larger than 1 cm in diameter. Although electrohydraulic lithotripsy (EHL) with a baby endoscope is useful in some cases [1], it can be difficult because of poor operability of the baby scope or incomplete irrigation with the EHL probe loaded in the working channel of the scope. Recently, the SpyGlass Direct Visualization System (SDVS; Boston Scientific, Natick, Massachusetts, USA) has allowed more effective diagnostic and therapeutic applications [2] [3]. Here we report the successful fragmentation of a large noncalcified pancreatic stone using SDVS-guided EHL.
TPF induction chemotherapy (CT) followed by concomitant cisplatin/radiotherapy (cCTRT) in locally advanced nasopharyngeal cancer (LANPC)
Authors: P. Bossi, D. Parolini, C. Bergamini, L. D. Locati, E. Orlandi, M. Franceschini, M. Palazzi, P. Olmi, P. Potepan, L. Licitra
Journal: Journal of Clinical Oncology (2009)

6046 Background: Recent meta-analysis showed better event free survival in LANPC with induction CT. In head and neck cancer, docetaxel, cisplatin and 5 FU (TPF) induction chemotherapy led to survival gain over cisplatin and 5FU alone. We studied feasibility and activity of TPF induction CT followed by cCTRT in LANPC. Methods: From October 2004 to May 2008, 45 pts with LANPC were treated at our Institution with 2 to 4 cycles (median 3) of induction TPF (docetaxel 75 mg/sm and cisplatin 75 mg/sm on day 1, and 5-FU 750 mg/sm/day ci for 96 hrs. Prophylactic ciprofloxacin was administered for 10 days each cycle, while use of G-CSF was not allowed. Following CT, pts received full doses radiotherapy (RT) concurrent with cisplatin 100 mg/sm q 21 days. Intensity modulated radiotherapy (IMRT) was delivered to 34 pts (76%). All but two pts had non-keratinizing carcinoma. Stage IV pts were 60%, stage III 34%, and 6% stage II. T4 was present in 24% and N3 disease was diagnosed in 42% of the pts. Results: TPF was well tolerated, with main toxicity consisting in neutropenia (31% G3–4). Response rate was 87%. RT dose ranged from 64 Gy to 70 Gy (median 70 Gy). Main toxicities during cCTRT were: neutropenia (38% G3, 4% G4), febrile neutropenia (11% G3), thrombocytopenia (7% G3–4) and mucositis (40% G3, 4% G4). Nasogastric tube was placed in 33% of pts and maintained for a median of 40 days. During cCTRT, platinum compounds mean dose delivery was 75%, with 6 pts shifting to carboplatin for renal function impairment. Observed late toxicities were xerostomia (G3 in 38% of cases) and peripheral neurotoxicity (G1 in 27%, G2 in 7% and G3 in 2% of the pts). After treatment completion, complete and partial response were recorded in 78% and 20% of the pts respectively, while 1 pt showed stable disease. With a median follow up of 22 months (range 7 to 47), 9 pts showed recurrence or progressive disease (7 at local and/or regional level, 2 distant metastases and 1 at both sites), with a 2-years event free survival of 78% and an overall survival of 85%. Conclusions: TPF followed by cCTRT is feasible in LANPC. In this high-stage nonendemic population local-regional disease control still remains the main therapeutic goal. Supported in part by AIRC. [Table: see text]